MannKind | MNKD - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Adma Biologics USD 20.19M 2.86M 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Insmed USD 212.48M 26.11M 2025-12
Karyopharm Therapeutics USD 27.19M 442K 2024-12
MacroGenics USD 7.94M 1.96M 2025-12
MannKind USD 29.09M 2.53M 2025-09
Merck USD 2.85B 215M 2025-12
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Novavax USD 25.53M 1.34M 2025-12
Novo Nordisk DKK 2.86B 13.25B 2025-06
Pfizer USD 4.08B 894M 2025-12
Sanofi EUR 2.75B 455M 2025-12
Xencor USD 17.04M 70.74M 2025-12